Actics Medical, a Sheba ARC portfolio company, is redefining diabetic foot care, a $60B U.S. burden that causes over one million amputations each year, with an AI-powered platform for continuous monitoring and personalized intervention. Its first product, the Hybrid+™ smart insole, combines real-time pressure, temperature, and gait sensing with adaptive offloading and reimbursement via RPM and orthotics codes. Pre-clinically validated at NYU and backed by top KOLs, Actics will launch clinical trials in early 2026 with a major US health system who plan adoption after the commercial pilot. Hybrid+ is the entry point to a next-generation closed-loop system, where agentic AI will deliver dynamic, self-adjusting remote care and scale into orthopedics, neurology, and sports. Actics is building a category-defining platform that saves lives and limbs, reduces costs by magnitude, and creates strong financial alignment with payers and providers